Early Trial Finds CAR T-Cell Therapy May Reduce Disability in Progressive MS
A small Phase 1 study from China reports that a single dose of equecabtagene autoleucel, a CAR T-cell therapy, led to reduced disability and improved function in three patients with progressive multiple sclerosis.